Loading
A phase 3 trial of Rovalpituzumab tesirine, Topotecan and Dexamethasone in Small-cell lung cancer, run by AbbVie, completed.
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) is a phase 3 interventional study registered as NCT03061812 by AbbVie, with 444 participants recorded, started 2017-04-11 and reaching its primary completion in 2020-02-12. Interventions recorded: Rovalpituzumab tesirine, Topotecan, Dexamethasone. Conditions recorded: Small Cell Lung Cancer.
Linked to the drug Rovalpituzumab tesirine because the registry names it among its interventions and Small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
444 enrolled.
95% CI 7.69 to 10.12; Figures from the ClinicalTrials.gov results section (first posted 2021-02-23), not from a publication · 95% CI 5.55 to 7.33
Source95% CI 3.75 to 5.42; Figures from the ClinicalTrials.gov results section (first posted 2021-02-23), not from a publication · 95% CI 2.86 to 3.61
Source95% CI 14.27 to 28.97; Figures from the ClinicalTrials.gov results section (first posted 2021-02-23), not from a publication · 95% CI 10.75 to 19.26
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS)primary | Topotecan | 148 | 8.57 months | 1.46 (1.17 to 1.82) | 0.0051 | link |
| Rovalpituzumab Tesirine | 296 | 6.34 months | ||||
| Progression Free Survival (PFS) | Topotecan | 148 | 4.27 months | 1.51 (1.22 to 1.87) | <0.0001 | link |
| Rovalpituzumab Tesirine | 296 | 3.02 months | ||||
| Objective Response Rate (ORR) | Topotecan | 129 | 20.9% | - | 0.3352 | link |
| Rovalpituzumab Tesirine | 287 | 14.6% |
Shares Rovalpituzumab tesirine, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone, Extensive-stage small-cell lung cancer and the tag pipeline.
Shares Rovalpituzumab tesirine, AbbVie (incl. ImmunoGen, Capstan), Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Topotecan, Small-cell lung cancer and the tag pipeline.
Shares Topotecan, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.